What Does BioNTech (BNTX) Trial Miss Mean For Its Oncology Pipeline?

BioNTech (NasdaqGS:BNTX) reported that its Phase 2/3 trial of BNT113 in head and neck cancer did not meet the progression-free survival primary endpoint. The company is keeping the trial active to continue evaluating overall survival as a key secondary outcome measure. BNT113 is part of BioNTech's mRNA-based oncology portfolio that targets HPV16-positive head and neck tumors. To put this update on BioNTech in context, consider reviewing other healthcare and AI-focused stocks via 33...